Structure-activity studies with Ginkgo biloba extract constituents as receptor-gated chloride channel blockers and modulators

Pharmacopsychiatry

Volumn 36, Issue SUPPL. 1, 2003, Pages

  Chatterjee, S S ^a   Kondratskaya, E L ^b   Krishtal, O A ^b  

^a DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

^b BOGOMOLETZ INSTITUTE OF PHYSIOLOGY   (Ukraine)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; BILOBALIDE; CHLORIDE CHANNEL BLOCKING AGENT; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C; GINKGOLIDE J; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NV 31; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; BINDING KINETICS; CALCIUM CURRENT; CHANNEL GATING; CONFERENCE PAPER; CONTROLLED STUDY; HIPPOCAMPUS; HOMEOSTASIS; IC 50; INHIBITION KINETICS; MODULATION; NERVE CONDUCTION; NONHUMAN; PLANT LEAF; POTASSIUM CURRENT; PRIORITY JOURNAL; RAT; SODIUM CURRENT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANIMALS, NEWBORN; CEREBELLUM; CHLORIDE CHANNELS; CYCLOPENTANES; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ELECTRIC CONDUCTIVITY; FURANS; GAMMA-AMINOBUTYRIC ACID; GINKGO BILOBA; GINKGOLIDES; GLYCINE; HIPPOCAMPUS; INHIBITORY CONCENTRATION 50; LACTONES; NEURONS; PATCH-CLAMP TECHNIQUES; PLANT EXTRACTS; PLATELET ACTIVATING FACTOR; PYRANS; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0042827333     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Ahlemeyer B, Junker V, Huhne R, Krieglstein J. Neuroprotective effects of NV-31, a bilobalide-derived compound: evidence for an antioxidative mechanism. Brain Res 2001; 890 (2): 38-342
2. Bhattacharya SK, Chakrabarti A, Chatterjee SS. Behavioural effects of bilobalide isolated from Ginkgo biloba leaves: Some experimental observations. Naunyn-Schmiedeberg's Arch Pharmacol 2002; 358 (Suppl. 2): R 489:P 5121
3. Braquet P. The ginkgolides: Potent platelet-activating factor antagonists isolated from Ginkgo biloba L: Chemistry pharmacology and clinical applications. Drugs of the Future 1987; 12: 43
4. Breitinger HG, Becker CM. The inhibitory glycine receptor: prospects for a therapeutic orphan? Curr Pharm Des 1998; 4 (4): 315-334
5. Brochet D, Chermat R, DeFeudis FV, Drieu K. Effects of single intraperitoneal injections of an extract of Ginkgo biloba (EGb 761) and its terpene trilactone constituents on barbital-induced narcosis in the mouse. Gen Pharmacol 1999; 33 (3): 249-256
6. Chatterjee SS. Species specific behavioral activity profile of bilobalide in mice. Presented at the 14th World Congress of Pharmacology (IUPHAR), 2002: abstr.77.6
7. Chatterjee SS, Klessing K, Jaggy H, Seederup E, Squires RF. Bilobalide and its structural analogs as novel chloride channel ligands without convulsant activity. Naunyn-Schmiedeberg's Arch Pharmacol 2002; 365: (Suppl. 1; R 79)
8. Chatterton JE, Awobuluyi M, Premkumar LS, Takahashi H, Talantova M, Shin Y et al. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature 2002; 415 (6873): 793-798
9. Chen Q, Olney JW, Lukasiewicz PD, Almli T, Romano C. Ca2+-independent excitotoxic neurodegeneration in isolated retina, an intact neural net: a role for Cl- and inhibitory transmitters. Mol Pharmacol 1998; 53 (3): 564-572
10. Continella G, Drago F. Behavioral effects of Ginkgo biloba extract. In effects of Ginkgo biloba extract on organic cerebral impairment. W V John Libbey Eurotext Ltd, 1985: 35-42
11. Davies JA, Jahns L, Jones FA. Effects of bilobalide on cerebral amino acid neurotransmission. Pharmacopsychiatry. 2003; this issue
12. DeFeudis FV. Ginkgo biloba extract (EGb761): from chemistry to the clinic. Ullstein Medical ed. Wiesbaden, 1998
13. Du XY, Li XY. Effect of ginkgolides on interleukin 1, tumor necrosis factor-alpha and nitric oxide production by rat microglia stimulated with lipopolysaccharides in vitro. Arzneimittelforsch 1998; 48: 1126-1130
14. Hu L, Chen Z, Cheng X, Xie Y. Chemistry of ginkgolides: structure-activity relationship as PAF antagonists. Pure Appl Chem 1999; 71 (6): 1153-1156
15. Inglefield JR, Schwartz-Bloom RD. Activation of excitatory amino acid receptors in the rat hippocampal slice increases intracellular Cl- and cell volume. J Neurochem 1998; 71 (4): 1396-1404
16. Janssens D, Delaive E, Remacle J, Michiels C. Protection by bilobalide of the ischaemia-induced alterations of the mitochondrial respiratory activity. Fundam Clin Pharmacol 2000; 14 (3): 193-201
17. Jones FA, Chatterjee SS, Davies JA. Effects of bilobalide an amino acid release and electrophysiology of cortical slices. Aminoacids 2002; 22: 369-379
18. Klaassen CD. Nonmetallic environmental toxicants. In Goodman and Gilman's. The Pharmacological Basis of Therapeutics, 2002: 1689-1690
19. Klein J, Chatterjee SS, Löffelholz K. Phospholipid breakdown and choline release under hypoxic conditions: inhibition by bilobalide, a constituent of Ginkgo biloba. Brain Res 1997; 755 (2): 347-350
20. Klein J, Weichel O, Hilgert M, Johanna R, Chatterjee SS, Nawrath H. Excitotoxic hippocampal membrane breakdown and its inhibition by bilobalide: Role of chloride fluxes. Pharmacopsychiatry, 2003; this issue
21. Klusa V, Germane S, Noeldner M, Chatterjee SS. Effects of bilobalide in two rodent learning models. Naunyn-Schmiedeberg's Arch Pharmacol 2002; 358 ((Suppl. 2): R 494-5143
22. Koch E, Chatterjee SS. Experimentelle Grundlage für die therapeutische Anwendung von Ginkgo biloba extrakt EGb 761®. Haemostaseologie 1993; 13: 11-27
23. Kondratskaya EL, Lishko PV, Chatterjee SS, Krishtal OA. BN52021, a platelet activating factor antagonist, is a selective biocker of glycinegated chloride channel. Neurochem Int 2002; 40 (7): 647-653
24. Krishtal O, Lozovaya N, Fisunov A, Tsintsadze T, Pankratov Y, Kopanitsa M et al. Modulation of ion channels in rat neurons by the constituents of Hypericum perforatum. Pharmacopsychiatry 2001; 34 Suppl 1: S74S82
25. Krishtal OA, Marchenko SM, Pidoplichko VI. Receptor for ATP in the membrane of mammalian sensory neurons. Neurosci Lett 1983; 35 (1): 41-45
26. Lambert N, Grover L. The mechanism of biphasic GABA responses. Science 1995; 269 (5226): 928-929
27. Lenoir M, Pedruzzi E, Rais S, Drieu K, Perianin A. Sensitization of human neutrophil defense activities through activation of platelet-activating factor receptors by ginkgolide B, a bioactive component of the Ginkgo biloba extract EGB 761. Biochem Pharmacol 2002; 63 (7): 1241-1249
28. Miller LG, Bazan NG, Roy RB, Clostre F, Gaver A, Braquet P. Platelet activating factor antagonists interact with GABAa receptors. Res Commun Chem Pathol Pharmaco11991; 74 (2): 253-256
29. Möhler M. (Editor): Pharmacology of GABA and glycine neurotransmission. Handb Exp Pharmacol Springer-Verlag, Berlin, Heidelberg: 2001: 150
30. Pietri S, Maurelli E, Drieu K, Culcasi M. Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J Mol Cell Cardiol 1997; 29(2): 733-742
31. Rundstrom N, Schmieden V, Betz H, Bormann J, Langosch D. Cyanotriphenylborate: subtype-specific blocker of glycine receptor chloride channels. Proc Natl Acad Sci U S A 1994; 91 (19): 8950-8954
32. Sasaki K, Oota I, Wada K, Inomata K, Ohshika H, Haga M. Effects of bilobalide, a sesquiterpene in Ginkgo biloba leaves, on population spikes in rat hippocampal slices. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1999; 124 (3): 315-321
33. Sasaki K, Hatta S, Wada K, Ohshika H, Haga M. Anticonvulsant activity of bilobalide, a sesquiterpene in Ginkgo biloba leaves, against chemical-induced and electroshock induced convulsions in mice. Res Commun Biol Psychiatry 1995; 20: 145-156
34. Song W, Guan HJ, Zhu XZ, Chen ZL, Yin ML, Cheng XF. Protective effect of bilobalide against nitric oxide-induced neurotoxicity in PC12 cells. Acta Pharmacol.Sin. 2000; 21: 415-420
35. Staley KJ, Soldo BL, Proctor WR. Ionic mechanisms of neuronal excitation by inhibitory GABAA receptors. Science 1995; 269 (5226): 977-981
36. Sun D, Murali SG. Stimulation of Na+-K+-2Cl-cotransporter in neuronal cells by excitatory neurotransmitter glutamate. Am J Physiol 1998; 275 (3 Pt 1): C772-779
37. Sun MK, Alkon DL. Pharmacological enhancement of synaptic efficacy, spatial learning, and memory through carbonic anhydrase activation in rats. J Pharmacol Exp Ther 2001; 297 (3): 961-967
38. Sun MK, Alkon DL. Carbonic anhydrase gating of attention: Memory therapy and enhancement. TIPS 2002; 23: 83-89
39. Von Beek TA. Ginkgo biloba. Harwood academic publishers, 2000
40. Weichel O, Hilgert M, Chatterjee SS, Lehr M, Klein J. Bilobalide, a constituent of Ginkgo biloba, inhibits NMDA-induced phospholipase A2 activation and phospholipid breakdown in rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 1999; 360 (6): 609-615
41. Wettstein A. Cholinesterase inhibitors and Gingko biloba extracts - are they comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy studies of at least six months' duration. Phytomedicine 2000; 6 (6): 393-401